Clinical Trial: NCT04923945
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hutchison Medipharma Limited |
| Information Provided By: | Hutchmed |
| Last Update Posted: | 2025-03-07 |
Study Overview
Brief Summary
Treating Non-small Cell Lung Cancer (NSCLC) Patients with MET exon 14mutations with Savolitinib
Official Title
A Multi-center, Open-label, Phase IIIb Confirmatory Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Locally Advanced or Metastatic NSCLC Patients With MET Exon 14mutations
Conditions
Non-small Cell Lung Cancer Metastatic
Intervention / Treatment
- Drug: Savolitinib
Other Study ID Numbers
- 2020-504-00CH2
Start Date (Actual)
2021-08-19
Primary Completion Date (Actual)
2024-11-30
Study Completion Date (Actual)
2024-11-30
Enrollment (Actual)
203
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hutchison Medipharma Limited |
| Information Provided By: | Hutchmed |
| Last Update Posted: | 2025-03-07 |
Study Overview
Brief Summary
Treating Non-small Cell Lung Cancer (NSCLC) Patients with MET exon 14mutations with Savolitinib
Official Title
A Multi-center, Open-label, Phase IIIb Confirmatory Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Locally Advanced or Metastatic NSCLC Patients With MET Exon 14mutations
Conditions
Non-small Cell Lung Cancer Metastatic
Intervention / Treatment
- Drug: Savolitinib
Other Study ID Numbers
- 2020-504-00CH2
Start Date (Actual)
2021-08-19
Primary Completion Date (Actual)
2024-11-30
Study Completion Date (Actual)
2024-11-30
Enrollment (Actual)
203
Study Type
Interventional
Phase
Phase 3